Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Fisher & Paykel Healthcare Corporation Ltd

Healthcare AU FPH

30.27AUD
-0.31(1.01%)

Last update at 2026-06-03T06:10:00Z

Day Range

29.8430.41
LowHigh

52 Week Range

26.5135.13
LowHigh

Fundamentals

  • Previous Close 30.58
  • Market Cap18235.32M
  • Volume459798
  • P/E Ratio51.75
  • Dividend Yield1.66%
  • EBITDA759.40M
  • Revenue TTM2308.40M
  • Revenue Per Share TTM3.93
  • Gross Profit TTM 1470.10M
  • Diluted EPS TTM0.60

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax 636.10M 503.30M 235.70M 328.00M 504.20M
Minority interest - - - - -
Net income 471.91M 377.20M 132.60M 250.30M 376.90M
Selling general administrative - 534.40M 492.80M 431.90M 393.10M
Selling and marketing expenses - 534.40M 492.80M 431.90M 393.10M
Gross profit 1511.63M 530.20M 1044.40M 945.90M 1013.40M
Reconciled depreciation - 139.90M 114.30M 99.00M 96.00M
Ebit 671.86M 514.40M 353.40M 334.70M 509.10M
Ebitda 831.61M 654.30M 444.80M 433.70M 605.10M
Depreciation and amortization 159.75M 139.90M 91.40M 99.00M 96.00M
Non operating income net other - - - - -
Operating income 671.86M -371.00000M 353.40M 310.80M 468.28M
Other operating expenses 1684.17M 1651.30M 1389.40M 34.05M 76.69M
Interest expense 10.37M 11.10M 18.20M 6.70M 4.90M
Tax provision - 126.10M 103.10M 77.70M 127.30M
Interest income - 4.30M 3.30M 2.60M 2.60M
Net interest income - -6.80000M -14.90000M -4.10000M -2.30000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 164.19M 126.10M 103.10M 77.70M 127.30M
Total revenue 2356.03M 1280.30M 1742.80M 1588.60M 1642.40M
Total operating expenses 839.77M 901.20M 691.00M 705.20M 643.10M
Cost of revenue 844.40M 750.10M 698.40M 642.70M 629.00M
Total other income expense net -35.75848M 874.30M -117.70000M -7.60000M 40.20M
Discontinued operations - - - - -
Net income from continuing ops - 377.20M 132.60M 250.30M 376.90M
Net income applicable to common shares - - - 250.30M 376.90M
Preferred stock and other adjustments - - - - -
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 2874.38M 2550.80M 2281.70M 2204.50M 2107.00M
Intangible assets 73.23M 82.10M 88.40M 85.60M 86.80M
Earning assets - - - - -
Other current assets 21.15M - 45.30M 68.90M 64.70M
Total liab 743.57M 660.40M 522.60M 451.10M 427.30M
Total stockholder equity 2130.80M 1890.40M 1759.10M 1753.40M 1679.70M
Deferred long term liab - - - - -
Other current liab 411.27M - 256.40M 230.90M 231.64M
Common stock 501.53M - 404.00M 303.70M 261.20M
Capital stock - 468.60M 404.00M 303.70M 261.20M
Retained earnings 1453.31M 1226.60M 1095.00M 1200.50M 1181.20M
Other liab - - - 36.80M 36.10M
Good will - - - - -
Other assets - - - 196.20M 174.40M
Cash 464.46M 264.50M 82.00M 121.00M 89.90M
Cash and equivalents - - - - -
Total current liabilities 501.42M 500.40M 385.00M 289.80M 303.90M
Current deferred revenue - - - -5.40032M 1.46M
Net debt -317.29353M - 107.10M 24.80M 14.40M
Short term debt 33.04M - 96.20M 21.30M 17.00M
Short long term debt - 64.00M 78.50M 4.20M 5.30M
Short long term debt total 147.16M - 189.10M 145.80M 104.30M
Other stockholder equity -5.23786M - - -1407.29444M -1335.92953M
Property plant equipment - - - 1148.20M 957.80M
Total current assets 1160.59M 935.40M 704.90M 774.20M 887.90M
Long term investments - - - - -
Net tangible assets - - - 1667.80M 1592.90M
Short term investments - - - 0.47M 200.00M
Net receivables 345.30M 267.30M 257.20M 218.50M 174.40M
Long term debt - - 35.70M 79.10M 63.00M
Inventory 329.68M 342.90M 320.40M 365.80M 358.90M
Accounts payable 57.11M 52.90M 32.40M 43.00M 53.80M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 181.21M - 260.10M 249.20M 237.30M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 55.90M 99.62M 90.81M
Deferred long term asset charges - - - - -
Non current assets total 1713.79M 1615.40M 1576.80M 1430.30M 1219.10M
Capital lease obligations - 89.30M 74.90M 62.50M 36.00M
Long term debt total - - - - -
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments - -103.00000M -339.00000M -11.30000M 80.30M
Change to liabilities - - - -19.00000M -5.70000M
Total cashflows from investing activities -196.62126M -103.00000M -339.00000M -11.30000M -89.50000M
Net borrowings - -56.90000M 30.60M -4.40000M -14.10000M
Total cash from financing activities -278.71466M -268.20000M -128.70000M -197.10000M -235.80000M
Change to operating activities - - - - -
Net income 471.91M 377.20M 132.60M 234.17M 349.08M
Change in cash 173.44M 179.30M -35.90000M 32.20M -0.80000M
Begin period cash flow 291.02M 80.90M 116.80M 84.60M 85.40M
End period cash flow 464.46M 260.20M 80.90M 116.80M 84.60M
Total cash from operating activities 668.03M 548.60M 429.60M 222.85M 300.36M
Issuance of capital stock - 3.10M 3.00M 3.00M 3.20M
Depreciation 159.75M - 109.10M 87.85M 80.30M
Other cashflows from investing activities - -29.40000M -22.20000M - -
Dividends paid 254.14M -195.90000M -145.50000M -195.70000M -224.90000M
Change to inventory 15.61M -22.50000M 45.40M -6.45548M -81.78215M
Change to account receivables -28.60678M -45.10000M -38.50000M -40.51047M 48.62M
Sale purchase of stock - - - 137.50M 7.50M
Other cashflows from financing activities -21.55581M -18.50000M -16.80000M -14.40000M -14.00000M
Change to netincome - - - -41.90000M -107.10000M
Capital expenditures 174.06M 103.00M 339.00M 211.30M 169.80M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 16.12M -67.60000M 6.90M -46.96595M -33.15743M
Stock based compensation - - 10.80M 8.42M 7.50M
Other non cash items 24.07M 616.20M 170.20M -99.17113M -129.01760M
Free cash flow 493.97M 445.60M 90.60M 11.55M 130.56M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FPH
Fisher & Paykel Healthcare Corporation Ltd		 -0.31 1.01% 30.27 51.75 42.37 7.90 11.31 15.26 29.64
RMD
Resmed Inc		 -0.18 0.69% 25.84 19.97 17.76 7.59 4.70 5.30 13.47
ANN
Ansell Ltd		 0.36 1.32% 27.60 20.82 16.61 1.91 1.40 1.66 11.05
NAN
Nanosonics Ltd		 -0.04 1.25% 3.16 45.57 46.30 4.60 4.41 3.93 25.73
SDI
SDI Ltd		 - -% 1.36 13.45 5.06 1.43 1.55 1.54 8.42

Reports Covered

Stock Research & News

View All

Profile

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, it provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.

Fisher & Paykel Healthcare Corporation Ltd

15 Maurice Paykel Place, Auckland, New Zealand, 2013

Key Executives

Name Title Year Born
Mr. Lewis G. Gradon MD, CEO & Exec. Director 1961
Ms. Lyndal York Chief Financial Officer NA
Dr. Andrew Somervell VP of Products & Technology NA
Hayden Brown Investor Relations Mang. NA
Karen Knott Gen. Mang. of Corp. Communications NA
Mr. Paul N. Shearer B.Com. Sr. VP of Sales & Marketing NA
Ms. Nicola Talbot VP of HR NA
Mr. Jonathan Rhodes VP of Supply Chain, Facilities & Sustainability NA
Mr. Marcus Driller VP of Corp. & Company Sec. NA
Chris Crone Gen. Mang. of Airvo Optiflow NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.